• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma.

作者信息

Shalhout Sophia Z, Park Jong Chul, Emerick Kevin S, Sullivan Ryan J, Kaufman Howard L, Miller David M

机构信息

Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts.

出版信息

J Am Acad Dermatol. 2021 Oct;85(4):1038-1040. doi: 10.1016/j.jaad.2021.01.048. Epub 2021 Jan 19.

DOI:10.1016/j.jaad.2021.01.048
PMID:33476726
Abstract
摘要

相似文献

1
Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma.晚期皮肤鳞状细胞癌中抗程序性细胞死亡蛋白1治疗反应的真实世界评估
J Am Acad Dermatol. 2021 Oct;85(4):1038-1040. doi: 10.1016/j.jaad.2021.01.048. Epub 2021 Jan 19.
2
Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.抗程序性细胞死亡蛋白1抑制剂用于晚期皮肤鳞状细胞癌和基底鳞状细胞癌的挽救治疗：5例初步经验
Br J Dermatol. 2016 Dec;175(6):1382-1386. doi: 10.1111/bjd.14642. Epub 2016 Oct 17.
3
Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.III期转移性皮肤鳞状细胞癌对程序性死亡-1抑制剂帕博利珠单抗的反应模式及获得性耐药
Dermatol Ther. 2019 Nov;32(6):e13107. doi: 10.1111/dth.13107. Epub 2019 Oct 21.
4
A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.一例对程序性细胞死亡蛋白1抑制剂帕博利珠单抗敏感的不可切除皮肤鳞状细胞癌病例报告
JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.
5
Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.程序性细胞死亡蛋白1抑制剂治疗皮肤鳞状细胞癌的随访
JAMA Dermatol. 2017 Jan 1;153(1):92-94. doi: 10.1001/jamadermatol.2016.3884.
6
Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.非黑色素瘤皮肤癌中的抗程序性细胞死亡-1疗法。
Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17.
7
Multiple keratin granulomata: A potential histologic clue to cutaneous squamous cell carcinoma responding to programmed cell death protein 1 inhibitor therapy.多发性角质形成细胞肉芽肿：皮肤鳞状细胞癌对程序性细胞死亡蛋白1抑制剂治疗有反应的潜在组织学线索。
J Cutan Pathol. 2019 Jun;46(6):452-454. doi: 10.1111/cup.13447. Epub 2019 Apr 4.
8
Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.帕博利珠单抗对中枢神经系统转移的梭形细胞鳞状细胞癌的持久反应。
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619850216. doi: 10.1177/2324709619850216.
9
Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.帕博丽珠单抗联合低分割放射治疗晚期不可切除皮肤鳞状细胞癌。
Eur J Dermatol. 2019 Dec 1;29(6):636-640. doi: 10.1684/ejd.2019.3671.
10
Dichotomic response patterns to PD-1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas.一名患有多种鳞状细胞癌的患者对西米普利单抗阻断PD-1的二分反应模式。
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):e547-e549. doi: 10.1111/jdv.18705. Epub 2022 Nov 7.

引用本文的文献

1
Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.年度重大进展：2023 - 2024年皮肤鳞状细胞癌免疫治疗的进展
Cancer. 2025 Jun 1;131(11):e35920. doi: 10.1002/cncr.35920.
2
The evolving treatment landscape for CSCC.皮肤鳞状细胞癌不断演变的治疗格局。
Arch Dermatol Res. 2025 Feb 26;317(1):502. doi: 10.1007/s00403-025-03933-5.
3
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma.
CCL-20 和 CXCL-8 基因的过表达增强了局部晚期和转移性皮肤鳞状细胞癌患者对程序性死亡蛋白-1（PD-1）抑制剂西米普利单抗的肿瘤逃逸和耐药性。
Oncoimmunology. 2024 Aug 26;13(1):2388315. doi: 10.1080/2162402X.2024.2388315. eCollection 2024.
4
Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices.美国肿瘤治疗实践中晚期皮肤鳞状细胞癌患者使用西米普利单抗的真实世界治疗模式及疗效
Cancer Manag Res. 2024 Jul 18;16:841-854. doi: 10.2147/CMAR.S445910. eCollection 2024.
5
Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022.免疫检查点抑制剂治疗眼眶和眼附属器鳞状细胞癌：国际眼肿瘤学会主席演讲，2022 年。
Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):29. doi: 10.1167/iovs.64.7.29.
6
Risk factors and novel predictive model for metastatic cutaneous squamous cell carcinoma: a population-based analysis.风险因素和转移性皮肤鳞状细胞癌的新型预测模型：基于人群的分析。
Arch Dermatol Res. 2023 Oct;315(8):2339-2346. doi: 10.1007/s00403-023-02616-3. Epub 2023 Apr 11.
7
Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis.免疫检查点抑制剂治疗晚期皮肤鳞状细胞癌：系统评价和荟萃分析。
Skin Res Technol. 2023 Jan;29(1):e13229. doi: 10.1111/srt.13229. Epub 2022 Nov 3.
8
Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey.抗 PD-1 治疗老年晚期皮肤鳞状细胞癌：法国多中心回顾性调查。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3549-3562. doi: 10.1007/s00432-022-04246-0. Epub 2022 Aug 12.
9
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy.免疫治疗时代的皮肤鳞状细胞癌
Cancers (Basel). 2021 Mar 8;13(5):1148. doi: 10.3390/cancers13051148.